The Role of R-Alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 1, 2011

Primary Completion Date

November 1, 2011

Study Completion Date

October 1, 2024

Conditions
Atherosclerosis
Interventions
DIETARY_SUPPLEMENT

R-alpha lipoic acid

300 mg R-alpha lipoic acid or placebo twice daily for 12 weeks, followed by a washout period of 12 weeks, followed by another treatment phase of the other treatment placebo or 300 mg R-alpha-lipoic acid for 12 weeks

Trial Locations (1)

97201

Oregon Health & Science University, Portland

All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

lead

Oregon State University

OTHER

NCT00764270 - The Role of R-Alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease | Biotech Hunter | Biotech Hunter